Martin Wehling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/885438/publications.pdf

Version: 2024-02-01

279487 233125 2,207 62 23 45 citations h-index g-index papers 73 73 73 2314 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Purification and Partial Sequencing of High-Affinity Progesterone-Binding Site(s) from Porcine Liver Membranes. FEBS Journal, 1996, 239, 726-731.	0.2	250
2	Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. European Journal of Clinical Pharmacology, 2014, 70, 1159-1172.	0.8	137
3	VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age and Ageing, 2016, 45, 262-267.	0.7	126
4	Specific Progesterone Binding to a Membrane Protein and Related Nongenomic Effects on Ca2+-Fluxes in Sperm. Endocrinology, 1999, 140, 5999-6002.	1.4	114
5	Assessing the translatability of drug projects: what needs to be scored to predict success?. Nature Reviews Drug Discovery, 2009, 8, 541-546.	21.5	114
6	Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age and Ageing, 2015, 44, 745-755.	0.7	105
7	STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age and Ageing, 2021, 50, 1189-1199.	0.7	88
8	Non-genomic steroid hormone effects: Membrane or intracellular receptors?. Journal of Steroid Biochemistry and Molecular Biology, 2006, 102, 180-183.	1.2	87
9	Translational medicine: can it really facilitate the transition of research "from bench to bedside�. European Journal of Clinical Pharmacology, 2006, 62, 91-95.	0.8	80
10	Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. European Geriatric Medicine, 2019, 10, 9-36.	1.2	79
11	The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs and Aging, 2018, 35, 61-71.	1.3	73
12	Translational medicine: science or wishful thinking?. Journal of Translational Medicine, 2008, 6, 31.	1.8	66
13	The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People. Drugs and Aging, 2019, 36, 481-484.	1.3	56
14	Interaction of Rapid Nongenomic Cardiovascular Aldosterone Effects with the Adrenergic System1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 761-767.	1.8	47
15	Morbus Diureticus in the Elderly: Epidemic Overuse of a Widely Applied Group of Drugs. Journal of the American Medical Directors Association, 2013, 14, 437-442.	1.2	47
16	Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016). Drugs and Aging, 2017, 34, 499-507.	1.3	43
17	A systematic review and novel classification of listing tools to improve medication in older people. European Journal of Clinical Pharmacology, 2019, 75, 619-625.	0.8	42
18	The New Topical Steroid Ciclesonide Is Effective in the Treatment of Allergic Rhinitis. Journal of Clinical Pharmacology, 1999, 39, 1062-1069.	1.0	40

#	Article	IF	CITATIONS
19	Translatability scoring in drug development: eight case studies. Journal of Translational Medicine, 2012, 10, 39.	1.8	37
20	The U.SFORTA (Fit fOR The Aged) List: Consensus Validation of a Clinical Tool to Improve Drug Therapy in Older Adults. Journal of the American Medical Directors Association, 2020, 21, 439.e9-439.e13.	1.2	33
21	Drug development in the light of translational science: shine or shade?. Drug Discovery Today, 2011, 16, 1076-1083.	3.2	31
22	Meta-analysis of Flecainide Safety in Patients with Supraventricular Arrhythmias. Arzneimittelforschung, 2002, 52, 507-514.	0.5	27
23	Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1-12.	0.8	26
24	The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs and Aging, 2022, 39, 245-247.	1.3	25
25	The Human Membrane Progesterone Receptor Gene: Genomic Structure and Promoter Analysis. DNA Sequence, 2001, 12, 13-25.	0.7	24
26	Chemical modification and structural analysis of the progesterone membrane binding protein from porcine liver membranes. Molecular and Cellular Biochemistry, 2001, 218, 71-79.	1.4	23
27	Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 14.	2.7	23
28	Rapid actions of aldosterone revisited: Receptors in the limelight. Journal of Steroid Biochemistry and Molecular Biology, 2018, 176, 94-98.	1.2	19
29	Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy. Seminars in Thrombosis and Hemostasis, 2014, 40, 121-128.	1.5	18
30	Effects of Aldosterone and Mineralocorticoid Receptor Blockade on Intracellular Electrolytes. Heart Failure Reviews, 2005, 10, 39-46.	1.7	17
31	Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. European Journal of Clinical Pharmacology, 2018, 74, 339-347.	0.8	17
32	Nongenomic Cardiovascular Effects of Triiodothyronine in Euthyroid Male Volunteers. , 0, .		15
33	Translatability score revisited: differentiation for distinct disease areas. Journal of Translational Medicine, 2017, 15, 226.	1.8	13
34	Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?. Clinical Therapeutics, 2004, 26, A21-A27.	1.1	12
35	Translational Science in Medicine. Pharmaceutical Medicine, 2006, 20, 303-310.	0.4	11
36	The JAPAN-FORTA (Fit fOR The Aged) list: Consensus validation of a clinical tool to improve drug therapy in older adults. Archives of Gerontology and Geriatrics, 2020, 91, 104217.	1.4	11

3

#	Article	IF	Citations
37	To be or not to be (a receptor). Steroids, 2007, 72, 107-110.	0.8	10
38	Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung, 2010, 60, 57-63.	0.5	10
39	Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients. Thrombosis Research, 2014, 134, 1014-1019.	0.8	10
40	Nongenomic actions of estrogens: Exciting opportunities for pharmacology. Maturitas, 2006, 54, 321-326.	1.0	9
41	The FORTA (Fit fOR The Aged)-EPI (Epidemiological) Algorithm: Application of an Information Technology Tool for the Epidemiological Assessment of Drug Treatment in Older People. Drugs and Aging, 2019, 36, 969-978.	1.3	9
42	Higher Fit-fOR-The-Aged (FORTA) Scores Comprising Medication Errors are Associated with Impaired Cognitive and Physical Function Tests in the VALFORTA Trial. Drugs and Aging, 2019, 36, 269-277.	1.3	9
43	A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs and Aging, 2020, 37, 539-548.	1.3	9
44	Hypoxia modulates rapid effects of aldosterone on oxidative metabolism in human calf muscle. Journal of Endocrinological Investigation, 2001, 24, 587-597.	1.8	8
45	Review/PerspectiveTranslational Medicine: What is it and what could it be?. Arzneimittelforschung, 2009, 59, 3-7.	0.5	8
46	Older People, a Plethora of Drugs, and Drug List Approaches: Useful, Efficacious, or a Waste of Time?. Journal of the American Medical Directors Association, 2016, 17, 1073-1075.	1.2	8
47	The FORTA (Fit fOR The Aged) App as a Clinical Tool to Optimize Complex Medications in Older People. Journal of the American Medical Directors Association, 2017, 18, 893.	1.2	8
48	Challenges of Longevity in Developed Countries: Vascular Prevention of Dementia as an Immediate Clue to Tackle an Upcoming Medical, Social and Economic Stretch. Neurodegenerative Diseases, 2011, 8, 275-282.	0.8	7
49	Deprescribing or represcribing: not just a semantic dilemma. European Geriatric Medicine, 2022, 13, 529-530.	1.2	6
50	Knowledge on and use of the FORTA ("Fit fOR The Agedâ€)-list and the FORTA App by general practitioners in Baden-Württemberg, Germany. European Geriatric Medicine, 2020, 11, 499-503.	1.2	4
51	Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease. Clinical Drug Investigation, 2000, 20, 19-24.	1.1	3
52	Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study. Zeitschrift Fur Gesundheitswissenschaften, 2014, 22, 89-99.	0.8	3
53	FORTA(Fit-fOR-The-Aged)-based medication optimization: retrospective analysis of experiences from an unconventional outpatient service. European Geriatric Medicine, 2020, 11, 1035-1041.	1.2	3
54	The Fit fOR The Aged (FORTA) project and its clinical implications. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 275-277.	1.5	3

#	Article	IF	CITATIONS
55	Biotin-Labelled and Photoactivatable Aldosterone and Progesterone Derivatives as Ligands for Affinity Chromatography, Fluorescence Immunoassays and Photoaffinity Labelling. FEBS Journal, 1996, 237, 514-518.	0.2	2
56	Who Protects Physicians and Patients from Guidelines?. Cardiology, 2012, 121, 56-58.	0.6	1
57	The history of RRSH meetings (Rapid responses to steroid hormones). Steroids, 2014, 81, 2-3.	0.8	1
58	Calling for an exponential escalation scheme in vaccine development for COVID-19. European Journal of Clinical Pharmacology, 2020, 76, 1471-1472.	0.8	1
59	New Thieme Research Awards: Call for Pacesetting Contributions to Drug Research. Drug Research, 2017, 67, 137-137.	0.7	O
60	New Thieme Research Awards: Call for Pacesetting Contributions to Drug Research. Drug Research, 2017, 67, 256-256.	0.7	0
61	Target profiling in terms of translatability and early translation planning. , 2021, , 123-132.		О
62	The Sex-Specific Impact of the FORTA (Fit-fOR-The-Aged) List on Medication Quality and Clinical Endpoints in Older Hospitalized Patients: Secondary Analysis of a Randomized Controlled Trial. Drugs - Real World Outcomes, 2022, , 1.	0.7	0